Literature DB >> 22543574

Amino-terminal pro-brain natriuretic peptide as a predictor of outcome in patients admitted to intensive care. A prospective observational study.

Lina De Geer1, Mats Fredrikson, Anna Oscarsson.   

Abstract

CONTEXT: Amino-terminal pro-brain-type natriuretic peptide is known to predict outcome in patients with heart failure, but its role in an intensive care setting is not yet fully established.
OBJECTIVE: To assess the incidence of elevated amino-terminal pro-brain natriuretic peptide (NT-pro-BNP) on admission to intensive care and its relation to death in the ICU and within 30 days.
DESIGN: Prospective, observational cohort study.
SETTING: A mixed non-cardiothoracic tertiary ICU in Sweden. PATIENTS AND MAIN OUTCOME MEASURES: NT-pro-BNP was collected from 481 consecutive patients on admission to intensive care, in addition to data on patient characteristics and outcome. A receiver-operating characteristic curve was used to identify a discriminatory level of significance, a stepwise logistic regression analysis to correct for other clinical factors and a Kaplan-Meier analysis to assess survival. The correlation between Simplified Acute Physiology Score (SAPS) 3, Sequential Organ Failure Assessment score (SOFA) and NT-pro-BNP was analysed using Spearman's correlation test. Quartiles of NT-pro-BNP elevation were compared for baseline data and outcome using a logistic regression model.
RESULTS: An NT-pro-BNP more than 1380 ng -l on admission was an independent predictor of death in the ICU and within 30 days [odds ratio (OR) 2.6; 95% confidence interval (CI), 1.5 to 4.4] and was present in 44% of patients. Thirty-three percent of patients with NT-pro-BNP more than 1380 ng -1, and 14.6% of patients below that threshold died within 30 days (log rank P=0.005). NT-pro-BNP correlated moderately with SAPS 3 and with SOFA on admission (Spearman's ρ 0.5552 and 0.5129, respectively). In quartiles of NT-pro-BNP elevation on admission, severity of illness and mortality increased significantly (30-day mortality 36.1%; OR 3.9; 95% CI, 2.0 to 7.3 in the quartile with the highest values, vs. 12.8% in the lowest quartile).
CONCLUSION: We conclude that NT-pro-BNP is commonly elevated on admission to intensive care, that it increases with severity of illness and that it is an independent predictor of mortality.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22543574     DOI: 10.1097/EJA.0b013e32835470a8

Source DB:  PubMed          Journal:  Eur J Anaesthesiol        ISSN: 0265-0215            Impact factor:   4.330


  4 in total

1.  The effect of anesthesia method on serum level of pro-brain natriuretic Peptide in patients undergoing orthopedic surgery.

Authors:  Alireza Mirkheshti; Masoume Heidari Farzan; Yashar Nasiri; Kamran Mottaghi; Ali Dabbagh
Journal:  Anesth Pain Med       Date:  2015-04-20

2.  Usefulness of N-terminal pro-B-type natriuretic peptide in patients admitted to the intensive care unit: a multicenter prospective observational study.

Authors:  Chin Kook Rhee; So Yeon Lim; Shin Ok Koh; Won-Il Choi; Young-Joo Lee; Gyu Rak Chon; Je Hyeong Kim; Jae Yeol Kim; Jaemin Lim; Sunghoon Park; Ho Cheol Kim; Jin Hwa Lee; Ji Hyun Lee; Jisook Park; Younsuck Koh; Gee Young Suh; Seok Chan Kim
Journal:  BMC Anesthesiol       Date:  2014-03-10       Impact factor: 2.217

3.  Retrospective study on prognostic importance of serum procalcitonin and amino-terminal pro-brain natriuretic peptide levels as compared to Acute Physiology and Chronic Health Evaluation IV Score on Intensive Care Unit admission, in a mixed Intensive Care Unit population.

Authors:  Chitra Mehta; Babita Dara; Yatin Mehta; Ali M Tariq; George V Joby; Manish K Singh
Journal:  Ann Card Anaesth       Date:  2016 Apr-Jun

4.  Comparison of prognostic value of N-terminal pro-brain natriuretic peptide in septic and non-septic intensive care patients.

Authors:  Namik Ozcan; Ayse Ozcan; Cetin Kaymak; Hulya Basar; Mustafa Kotanoglu; Bektas Kose
Journal:  Arch Med Sci       Date:  2017-02-15       Impact factor: 3.318

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.